H.C. Wainwright downgraded Inhibikase Therapeutics (IKT) to Neutral from Buy without a price target after risvodetinib development was paused following results from the Phase 2 trial. The firm cites the company’s decision to halt further development of risvodetinib for the downgrade.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.